What Are the Most Effective Treatments for Prolonged Grief Disorder?

What Is Prolonged Grief Disorder?

Both the DSM-5-TR and ICD-11 diagnostic manuals now recognize prolonged grief disorder as a medical condition. The hallmark is persistent, intense grief that significantly impairs daily functioning.

Under DSM-5-TR criteria, symptoms must last for at least 12 months to qualify for a diagnosis. The ICD-11 criteria require symptoms to persist for at least 6 months.

Previously called Persistent Complex Bereavement Disorder in earlier drafts, the condition is sometimes referred to as complicated grief disorder. Research indicates the condition affects approximately 7 to 10% of bereaved adults.^1,2

To help individuals recognize the condition, providers look for several core symptom dimensions. These symptoms must represent a significant departure from cultural or religious norms:

• Persistent yearning: You experience intense longing or preoccupation with the deceased person.
• Identity and role confusion: You feel that a part of you died with the person.
• Emotional numbness: You have profound difficulty experiencing positive emotions.
• Difficulty accepting the loss: You experience disbelief or an inability to acknowledge the death's permanence.
• Avoidance of reminders: You steer away from people, places, or activities connected to the loss.
• Difficulty re-engaging with life: You withdraw from relationships, work, or future planning.
• Emotional pain: You feel intense sorrow, bitterness, or anger related to the death.

Prolonged grief disorder has a distinct neurobiology — one that helps explain why it resists time and why standard depression treatments often fall short.

Researchers believe the condition may involve dysregulation of the HPA axis, the system that governs your body's stress response, along with hyperconnectivity in the default mode network — the brain system associated with rumination, self-referential thinking, and the kind of looping thoughts that make grief feel inescapable.¹² Evidence also suggests that chronic grief may be associated with synaptic changes that reinforce these entrenched patterns, making them harder to shift through willpower or time alone.¹³

This is not a metaphor for being stuck. It is a description of what may be physically happening in the brain. And it helps explain why the treatments that work for depression — which target different biological pathways — do not always reach the grief itself.

Complicated Grief Treatment: The Most Evidence-Backed Psychotherapy for Prolonged Grief Disorder

Complicated Grief Treatment, also called Prolonged Grief Disorder Therapy, is the most evidence-backed psychotherapy for this condition, developed specifically for complicated grief rather than adapted from general depression or trauma therapy.

The protocol targets grief-specific mechanisms rather than general depression or anxiety pathways, combining cognitive behavioral techniques with grief-focused work.

A trained specialist guides you through revisiting the loss narrative to help process the reality of the death. The therapy also addresses avoidance behaviors, helping you slowly re-engage with activities or places you have been avoiding.

The protocol involves cognitive restructuring for grief-related thought patterns. Specialists help you identify and reframe unhelpful beliefs about the loss, while simultaneously rebuilding your identity and future orientation.

Response rates of 66 to 83% across three randomized controlled trials demonstrate the therapy's efficacy. The efficacy of Complicated Grief Treatment is supported by three major randomized controlled trials:

• Shear et al. 2005 (n=95): The treatment achieved a 66% response rate among completers compared to 32% for interpersonal therapy.³
• Shear et al. 2014 (n=151): In a trial of older adults, the protocol achieved a 69% response rate compared to 32% for interpersonal therapy.⁴
• Shear et al. 2016 (n=395): The therapy achieved an 82.5% response rate in the largest trial to date.⁵

The treatment typically requires 16 sessions over approximately 20 weeks. It must be delivered by a specially trained therapist.

You will most commonly find these specialists at academic medical centers or specialty grief clinics. Because of the specialized training required, finding a local provider represents a real access barrier for most people.

Complicated Grief Treatment remains the most evidence-backed option available today, limited primarily by access and time rather than efficacy. For people who can access a trained provider, it should be the first-line consideration.

Antidepressants: What the Evidence Actually Shows

Antidepressants are commonly prescribed after a loss, especially when grief co-occurs with depression. But the logic that works for depression does not apply to grief.

The medical evidence tells a different story regarding symptoms unique to grief. Two key trials highlight the limitations of standard pharmacotherapy for prolonged grief:

• Shear et al. 2016 (citalopram): In the largest grief pharmacotherapy trial (n=395), the SSRI citalopram was no better than placebo for grief at 12 or 20 weeks. Adding citalopram to Complicated Grief Treatment added nothing to grief outcomes, though it did improve co-occurring depression.⁵
• Reynolds et al. 1999 (nortriptyline): In a four-arm randomized controlled trial (n=80), the tricyclic antidepressant nortriptyline significantly improved depression but showed no differential effect on grief. Grief fell the same amount in every arm, whether participants received the antidepressant or placebo.⁶

Antidepressants are well-established treatments for depression and may be helpful when depression co-occurs with prolonged grief disorder. However, they have not been shown to treat the grief itself.

Medication may be appropriate when someone has co-occurring depression alongside prolonged grief disorder. The field's own conclusion from the 2016 Shear study is that "complicated grief is a specific condition in need of a specific treatment."⁵ Standard antidepressants alone rarely resolve the core symptoms of prolonged grief.

Ketamine-Assisted Therapy: Mindbloom's Published Outcomes

Mindbloom's published outcomes of 503 bereaved adults is the first publicly available outcomes analysis of ketamine-assisted therapy for prolonged grief disorder in particular.⁷ With 503 participants, it is also the largest real-world cohort by sample size, released as a preprint on Research Square.

The outcomes data demonstrates rapid and substantial changes in grief symptoms. Among people who completed treatment, the results showed:

• 90% reported any improvement in their symptoms.
• 76% response rate (defined as a 5-point or greater reduction on the PGD-13 scale).
• 73% no longer met ICD-11 diagnostic criteria for prolonged grief disorder.
• 71% no longer met DSM-5-TR diagnostic criteria.
• Rapid relief: The biggest single improvement came within the first two sessions.

These outcomes are specific to Mindbloom's protocol, which includes comprehensive medical evaluation, dedicated guide coaching, integration support, and ongoing oversight across six guided sessions. Results may differ with other providers or care models.

Across separate studies, treatment outcomes and normalized symptom improvement appear broadly comparable, although differences in study design, patient populations, and outcome measures limit definitive conclusions.⁷ No trial has directly compared these treatments head-to-head. Where scales differ, scores are normalized for scale range. Each figure reflects a study's own within-group change.

Mindbloom's 76% responder figure falls within the 66 to 83% range reported for Complicated Grief Treatment. On normalized symptom improvement using POMP methodology, Mindbloom achieved 41.8% compared to 41.7% for Complicated Grief Treatment.⁵

On diagnostic remission, Mindbloom's 73.2% (ICD-11) and 71.1% (DSM-5-TR) sit inside the 57 to 81% post-treatment range reported in published cognitive behavioral therapy trials.¹⁰

The most notable difference is the speed and accessibility of care. Complicated Grief Treatment requires 16 sessions over approximately 20 weeks in a specialty clinic.

Mindbloom's outcomes came from 6 sessions over approximately 4 to 6 weeks at home. Furthermore, 52% of participants responded by session 2. For people who had been grieving for a median of 18 months — many of them past the point where time alone was going to help — that timeline is significant.⁷

The symptom that improved most was identity and role confusion — the disorientation of no longer knowing who you are without the person you lost. It improved in 77% of completers. This is a grief-specific symptom that has nothing to do with depression, and it is precisely the symptom that antidepressants leave untouched.

The research is a retrospective cohort analysis, meaning outcomes are observed rather than proven caused by a controlled variable. For broader safety context, a separate peer-reviewed study of 11,441 Mindbloom patients found that serious adverse events occurred in fewer than 0.1% of sessions.¹¹

Common side effects like nausea or dizziness appeared in approximately 4 to 5% of sessions.¹¹ You can learn more about Mindbloom's grief outcomes research and the grief program online.

How to Choose: A Framework for Deciding

Choosing the right treatment depends on your access to care, your timeline, and what you have already tried. You must also consider whether co-occurring conditions are present.

The table below outlines common situations and evidence-based considerations.

When evaluating your options, it is helpful to ask potential providers specific questions. Consider asking:

• Have you been trained in Complicated Grief Treatment specifically?
• What is your experience treating prolonged grief disorder versus general bereavement?
• What outcomes data do you have for your approach?

Mindbloom offers programs of 6, 12, or 18 sessions. For pricing details and program options, visit Mindbloom's prolonged grief disorder page.

To explore whether the approach is right for you, visit the prolonged grief disorder condition page. You can also take a brief assessment to get started.

Conclusion

If you have been told that grief just takes time, the evidence suggests something more specific is true: prolonged grief disorder is a distinct medical condition, and it responds to treatments designed for it.

While antidepressants can address co-occurring depression, they have not been shown to treat the underlying grief itself. Complicated Grief Treatment remains the most rigorously studied psychotherapy, with response rates of 66 to 83% for those who can access a specialized clinic.

Ketamine-assisted therapy through Mindbloom has delivered comparable directional outcomes to Complicated Grief Treatment in a fraction of the time, entirely through at-home ketamine therapy.

The first step toward healing is recognizing that what you are experiencing has a name and that effective options exist. For more details on the treatment process, explore integration support and safety information.

Important Safety Information

Ketamine is not FDA-approved for PTSD, depression, or anxiety. Common side effects include dissociation, increased blood pressure, nausea, dizziness, and cognitive impairment.¹⁴ Ketamine has abuse potential and is not appropriate for patients with uncontrolled hypertension, psychotic disorders, or substance use disorders. Do not drive or operate machinery until the day after treatment. Individual results may vary. Full safety information: www.mindbloom.com/safety-information

Off-Label Use Disclosure

Ketamine is FDA-approved only as an anesthetic. Use for mental health conditions represents off-label prescribing by licensed clinicians based on clinical judgment.⁹ Schedule III Controlled Substance - DEA regulations apply.